Clearside valuation attractive ahead of potential catalysts, says Wedbush. Wedbush analyst Liana Moussatos maintained an Outperform rating and $29 price target on Clearside Biomedical shares, saying the current valuation is attractive in front of multiple potential catalysts, including the Phase 2 TYBEE data for suprachoroidal CLS-TA in DME in Q2, preliminary data from the Phase 3 SAPPHIRE trial for MERVO in Q4, and NDA submission for ME-NIU to the FDA in Q4.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.